Lung Cancer: VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung
What is the safety and tolerability of VX15/2503 when given in combination with avelumab
and what dose level of VX15/2503 to be given with 10 mg/kg of avelumab every 2 weeks?
Basic Study Information
Purpose:Location: Cancer Center
There are 2 phases in this study. If you are in the dose finding phase of the study,
the dose level of VX15/2503 that you receive is depends on when you enter the study.
The first group of subjects in this study will get a low dose of VX15/2503. If that
dose is well tolerated by those subjects, then the next group of subjects will get
a higher dose of VX15/2503. This will continue until the highest tolerable, safe dose
of VX15/2503 is reached. The dose expansion phase will begin begin after the highest
tolerable dose, or recommended phase 2 dosage (dose to be tested in expansion), has
been identified in the dose finding phase of the trial.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03268057?term=VX15%2F2503-04&rank=1
Study Reference #: ILUN17100
Lead Researcher (Principal Investigator)
Lead Researcher: Megan Baumgart
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Learn More About These Conditions
More information about Lung Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search